This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT01438073 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Massachusetts General Hospital |
| Enrollment | 96 participants |
| Design | Interventional, Na, Single Group, Masking: None |
| Conditions | Hypogonadotropic Hypogonadism; Healthy Postmenopausal Women; Agonadism |
| Interventions | kisspeptin 112-121; GnRH |
| Start | Sep 2011 |
| Primary completion | Apr 2016 |
| Study completion | Apr 2016 |
| Results posted | Not yet |
| Registry last updated | Jul 11, 2022 |
Compounds on this site that cite this trial
What the registry says the trial is about
The investigators are looking for subjects to complete a study on the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that tells the body to produce other reproductive hormones. However, giving someone a continued amount of kisspeptin over a period of time can have the opposite effect and tell the body to, for a short time, stop making hormones needed for reproduction. By giving 24-hour infusions of kisspeptin, the investigators hope to learn more about the role kisspeptin has in the way bodies function normally and the role it has in conditions that affect the reproductive system.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Average difference in Luteinizing Hormone (LH) concentration at the beginning and end of kisspeptin infusion | 24 hours |
2 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 3, 2026. See the trial changes feed for what has changed recently.
More trials of Kisspeptin-10
- Kisspeptin-10 and Leuprolide acetate: Phase 2 Trial (NCT05896293)
- Kisspeptin-10 and GnRH: Phase 2 Trial (NCT04648969)
- TAK-448: Phase 2 Trial (NCT02369796)
- Kisspeptin-10: Phase 1 Trial (NCT05633966)
Research area: Sexual health and melanocortin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.